Literature DB >> 8097708

Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1.

K E Thummel1, E D Kharasch, T Podoll, K Kunze.   

Abstract

The volatile anesthetic agent enflurane undergoes oxidative metabolism in human liver, yielding both inorganic and organic fluoride metabolites. Numerous studies conducted in animals indicate that the enzyme cytochrome P-450 2E1 is a major catalyst for the defluorination reaction. However, the P-450 enzyme catalyzing enflurane metabolism in humans has not been identified. Therefore, experiments were conducted to determine whether hepatic P-450 2E1 is a catalyst for the reaction in humans, and whether other constitutive or inducible isoforms might also be involved. Purified human liver P-450 2E1, reconstituted with cytochrome b5 and P-450 reductase, catalyzed enflurane defluorination at a rate of 9.3 nmol F-/nmol P-450/30 min, in contrast to a mean liver microsomal rate of 2.0 nmol F-/nmol P-450/30 min. The microsomal rate of defluorination for individual human livers correlated significantly with the microsomal content of P-450 2E1 protein (r = 0.92), the rate of p-nitrophenol hydroxylation (r = 0.86), and the rate of chlorzoxazone 6-hydroxylation (r = 0.90). In addition, specific anti-P-450 2E1 IgG, at a concentration of 10 mg IgG/nmol P-450 inhibited the microsomal reaction by 80%. Finally, a series of P-450 isoform-specific chemical inhibitors of oxidative metabolism--furafylline (1A2), sulfaphenazole (2C9/10), quinidine (2D6), troleandomycin (3A3/4), and diethyldithiocarbamate (2E1)--were screened for their ability to block human microsomal enflurane defluorination. Only diethyldithiocarbamate, a mechanism-based inhibitor of P-450 2E1, inhibited the reaction; this occurred to a degree comparable to the effect of anti-P-450 2E1 antibody.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097708

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  Contributions of human cytochrome P450 enzymes to glyburide metabolism.

Authors:  Lin Zhou; Suresh B Naraharisetti; Li Liu; Honggang Wang; Yvonne S Lin; Nina Isoherranen; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Biopharm Drug Dispos       Date:  2010-05       Impact factor: 1.627

2.  Involvement of human liver cytochrome P4502B6 in the metabolism of propofol.

Authors:  Y Oda; N Hamaoka; T Hiroi; S Imaoka; I Hase; K Tanaka; Y Funae; T Ishizaki; A Asada
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

Review 3.  Comparative tolerability profiles of the inhaled anaesthetics.

Authors:  J P Fee; G H Thompson
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 4.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

5.  The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes.

Authors:  V Spaldin; S Madden; W F Pool; T F Woolf; B K Park
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

6.  Maternal-fetal disposition of glyburide in pregnant mice is dependent on gestational age.

Authors:  Diana L Shuster; Linda J Risler; Chao-Kang J Liang; Kenneth M Rice; Danny D Shen; Mary F Hebert; Kenneth E Thummel; Qingcheng Mao
Journal:  J Pharmacol Exp Ther       Date:  2014-06-04       Impact factor: 4.030

7.  The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects.

Authors:  Satish Kumar Bedada; Prasad Neerati
Journal:  Eur J Clin Pharmacol       Date:  2017-10-05       Impact factor: 2.953

8.  Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Authors:  Y Shirasaka; A S Chaudhry; M McDonald; B Prasad; T Wong; J C Calamia; A Fohner; T A Thornton; N Isoherranen; J D Unadkat; A E Rettie; E G Schuetz; K E Thummel
Journal:  Pharmacogenomics J       Date:  2015-09-01       Impact factor: 3.245

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.